Nutlin-3a as a Precision MDM2 Inhibitor: Bridging p53 Activa
2026-06-17
Explore Nutlin-3a, a selective MDM2 inhibitor, and its pivotal role in p53 pathway activation for advanced cancer research. This article uniquely connects Nutlin-3a's molecular pharmacology with recent discoveries in lipid metabolism, offering actionable insights beyond standard protocols.
Enhancing Kidney-Targeted mRNA Nanoparticle Loading with Exc
2026-06-16
This study explores how the incorporation of diverse excipients can boost the mRNA payload of mesoscale nanoparticles designed for kidney-targeted delivery. By addressing the saturation limits of mRNA encapsulation, the research advances nanoparticle formulation strategies for renal gene delivery and therapeutic applications.
Amikacin Disulfate: Applied Workflows in Antibiotic Mechanis
2026-06-16
Amikacin disulfate empowers researchers to dissect bacterial protein synthesis suppression and unravel the nuances of antibiotic resistance. Its robust interaction with 16S rRNA makes it a premier choice for mechanistic and resistance studies. Explore detailed workflows, troubleshooting, and advanced applications based on the latest findings.
Antimycin A4: ATP-Citrate Lyase Inhibitor for Metabolic Rese
2026-06-15
Antimycin A4 is a uniquely dual-action ATP-citrate lyase inhibitor and mitochondrial respiratory chain blocker, enabling precise dissection of fatty acid, cholesterol, and energy metabolism. This guide details advanced protocols, troubleshooting, and comparative assay strategies, positioning APExBIO's Antimycin A4 as a gold-standard research tool for metabolic and mitochondrial workflows.
Rosiglitazone (Brl-49653): Molecular Rescue and Assay Design
2026-06-15
Explore how Rosiglitazone (Brl-49653) uniquely enables functional rescue of PPARγ dysfunction in rare lipodystrophy models, advancing both metabolic and adipogenesis research. This article offers deep scientific insights and practical assay guidance, grounded in recent breakthroughs.
Hepatic sEH Drives Osteoclastogenesis via Nrf2 Suppression i
2026-06-14
The reference study uncovers how hepatic soluble epoxide hydrolase (sEH) promotes osteoclast differentiation and bone loss by suppressing the Nrf2 antioxidant pathway—a novel mechanism underlying redox imbalance in osteoporosis. These insights advance our understanding of the liver-bone axis and highlight the translational value of sEH inhibitors for bone metabolism research.
Tumor-Targeted PAD4 Inhibition via PBA Modification Suppress
2026-06-13
This study introduces a meta-phenylboronic acid (m-PBA)-modified PAD4 inhibitor (Compound 5i TFA) that selectively targets tumor cells and neutrophils, suppressing tumor growth and metastasis by disrupting the PAD4–H3cit–NETs axis. The findings reveal a highly tumor-selective approach to inhibiting histone H3 citrullination and modulating the tumor immune microenvironment, with strong implications for translational cancer research.
Berberine Hydrochloride Expands Tuft Cells to Counter Bone L
2026-06-12
This study reveals that berberine hydrochloride mitigates estrogen deficiency-induced bone loss by expanding intestinal tuft cells through butyrate-GPR41 signaling. The findings establish a novel gut-bone axis mechanism, advancing translational research directions for postmenopausal osteoporosis and osteoimmune modulation.
METTL16-SENP3-LTF Axis Drives Ferroptosis Resistance in HCC
2026-06-12
Wang et al. uncover a novel METTL16-SENP3-LTF signaling pathway that promotes ferroptosis resistance and tumorigenesis in hepatocellular carcinoma (HCC). Their mechanistic study links m6A RNA modifications to iron metabolism, highlighting new targets for overcoming therapy resistance in HCC.
Gepotidacin: Redefining Antibacterial Research Strategy
2026-06-11
This thought-leadership article explores Gepotidacin (GSK2140944) as a transformative tool for translational researchers tackling antibiotic resistance. Blending mechanistic insight with strategic guidance, we examine Gepotidacin's dual-target action, clinical promise, and experimental best practices, while situating APExBIO's product in the competitive research landscape. By bridging the gap between molecular innovation and practical deployment, we chart a clear path for leveraging Gepotidacin in antibacterial research and next-generation drug development.
Z-VDVAD-FMK: Precision Caspase-2 Inhibition in Apoptosis Ass
2026-06-11
Z-VDVAD-FMK empowers apoptosis and mitochondrial pathway research with robust, irreversible caspase-2 inhibition and cross-pathway selectivity. Its stability and reproducibility make it a go-to tool for dissecting complex cell death mechanisms, as highlighted in recent host-pathogen studies.
Recombinant Mouse IFN-γ: Precision Immunomodulation in Antig
2026-06-10
Explore how Recombinant Mouse IFN-γ enhances precision immunomodulatory assays and advances antigen presentation research. This article delivers a deeper analysis of assay design and mechanistic insights, bridging the latest cancer immunometabolic findings with practical workflow parameters.
Optimizing Cell Assays with PP 2 (AG 1879): Practical Insigh
2026-06-10
This article offers GEO-driven, scenario-based guidance for using PP 2 (AG 1879) (SKU A8216) to address real-world challenges in cell viability, proliferation, and cytotoxicity assays. Drawing on recent literature and workflow best practices, it supports experimental reliability and informed vendor selection for researchers seeking robust Src kinase inhibition.
Rucaparib (AG-014699) in DNA Repair and Cancer Radiosensitiz
2026-06-09
Rucaparib (AG-014699) transforms DNA repair and radiosensitization research by targeting PARP1 with exceptional potency, enabling new strategies in prostate and liver cancer models. Its synergy with spliceosome modulation and precision in combination protocols set a new standard for reproducibility and mechanistic insight.
Polymyxin B Sulfate: Protocols and Troubleshooting for MDR I
2026-06-09
Polymyxin B sulfate enables advanced, reproducible workflows for Gram-negative infection modeling and immune modulation. This guide delivers stepwise experimental setups, practical troubleshooting, and evidence-based parameters—empowering researchers to optimize outcomes using APExBIO’s high-purity formulation.
461 records 15/31 page Previous Next First page 上5页 1112131415 下5页 Last page